title: Is graft-versus-leukemia more effective using reduced-intensity conditioning compared with myeloablative conditioning?
authors.affiliation: Division of Therapeutic Immunology and Center for Allogeneic Stem Cell Transplantation, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. Olle.Ringden@ki.se
authors.forename: Olle
authors.initials: O
authors.lastname: Ringdén
authors.forename: Behnam
authors.initials: B
authors.lastname: Sadeghi
mesh_terms: D000208:Acute Disease; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000276:immunology / Q000401:mortality / Q000473:pathology; D020544:Graft vs Leukemia Effect; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods*
chemical_list: D019653:Myeloablative Agonists